Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
Date:8/1/2014

; the protocol, design, scope, enrollment, timing, expectations and other aspects of Arena's or its collaborators' studies or trials; patent coverage; embracing the challenge of improving health; seeking to bring innovative medicines to patients; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of d
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
2. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
3. Healthcare Companies Announce Drug Launches, Upcoming Conference Calls, and Financial Results Schedules - Research Report on Bristol-Myers Squibb, Teva, Jazz, AmerisourceBergen and Arena
4. Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
5. Arena Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
6. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference
10. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
11. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Mass. , Sept. 17, 2014 /PRNewswire/ ... disease/ulcerative colitis (CD/UC) patients eligible for biologic ... receive a biologic. Surveyed gastroenterologists cite patients, ... reason for low penetration rates, followed by ... and UC patients receiving biologics, Janssen Biotech,s ...
(Date:9/17/2014)... MARINA DEL REY, Calif. , Sept. 17, ... launch of the Prostate Vanguard, an awareness campaign to ... replace multiple rectal needle biopsies of the prostate. ... of the prostate gland through the rectum. Multi-parametric MRI ... for diagnosing clinically-significant prostate cancer (CSPC). Men need ...
(Date:9/17/2014)... 2014 Bronstein, Gewirtz & Grossman, LLC is ... securities of PDL BioPharma, Inc. ("PDL BioPharma" or the ... are advised to contact Peretz Bronstein or ... info@bgandg.com or 212-697-6484. The investigation ... executives violated federal securities laws. On September ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, ... of DVT and its risk factors among patients with co-morbid ... respiratory and obesity patients.   DVT remains the ... deaths may be due to PE (pulmonary embolism).(1)  This is ...
... Ill., March 9, 2011 Hospira, Inc. (NYSE: ... announced U.S. Food and Drug Administration (FDA) approval of docetaxel. ... Hospira expects to launch the product later this month. ... variety of cancers. In 2010, U.S. sales of Taxotere were ...
Cached Medicine Technology:Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 2Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 3Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 4Hospira Announces U.S. Approval of Generic Docetaxel 2
(Date:9/17/2014)... New York, NY (PRWEB) September 17, 2014 ... morcellators ( http://www.drugbot.com/morcellator/ ) in laparoscopic hysterectomies and other ... LLP reports. According to figures posted on Change.org, at ... September 17th. * , According to a recent report ... one year ago by Dr. Hooman Noorchashm, after his ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Leading ... announce the launch of its new vegan and gluten-free ... extremely effective and provided the results skincare testers were ... create a gentle yet active mask that provided results, ... Louise.” , This Sugar Cane Fruit Mask combines Willow ...
(Date:9/17/2014)... Cadiz Laser Spa offers the ... to clients throughout Central Texas. The newest addition ... Induction Therapy. Using the revolutionary Rejuvapen micro-needling device ... clients correct a wide variety of skin issues. ... Cadiz Laser Spa is currently offering a special ...
(Date:9/17/2014)... 2014 The in vitro diagnostics (IVD) ... market, focusing on molecular diagnostics for conditions such as ... testing. The IVD market value is projected to be ... 2017. The major drivers of the market’s growth include ... is evidenced by the explosion for raid and minimally-invasive ...
(Date:9/17/2014)... Charlotte, NC (PRWEB) September 17, 2014 ... grant of $50,000 to the National Children’s Oral Health ... and education through NCOHF’s Orange County Oral Health Zone ... Health Zone Program is engaging a range of local ... breaking the cycle of severe tooth decay and its ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
... (Pink Sheets: SNDY) is pleased to announce that ... was featured in the "Cover Products" section ... issue. The article focused on the MammoView(TM),s functionality ... in the mammary ducts.The MammoView(TM) product line employs ...
... Together Extensive State/Local Resources and Makes Medical History ... solution for families, consumers and professionals concerned with ... to all New Yorkers. The New York ... www.nycnetworkofcare.org ) is an online clearinghouse that provides ...
... Medicare Reimbursement will have Significant Impact on the ... Mass., Feb. 19 Millennium Research Group (MRG) ... for Urological Devices 2008 report to reflect ... Due mainly to a favorable upgrade in Medicare ...
... Top 100 Has Placed McLaren In Top 25 Nationwide Since ... The SDI Top 100, an annual list that ranks the ... has ranked Flint-based McLaren Health Care the top-rated health system ... the nation, placing it 16th on this year,s list.McLaren has ...
... - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) ... the fourth quarter ending December 31, 2008 and full year ... specified otherwise, all amounts are in U.S. dollars and in ... for us as we concluded a series of corporate development ...
... Fla., Feb. 19 Smith & Nephew,s Advanced Wound ... announced that the United States Patent and Trademark Office ... negative pressure wound therapy (NPWT) patents during re-examination of ... Patent Office found that prior art showed that almost ...
Cached Medicine News:Health News:Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine 2Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 2Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 3Health News:Intermittent Catheter Market to Surpass 40% CAGR Between 2008 and 2012 2Health News:National Health Care List Ranks McLaren Health Care Top in Michigan; 16th in Nation 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 3Health News:QLT Announces Fourth Quarter and Year End 2008 Results 4Health News:QLT Announces Fourth Quarter and Year End 2008 Results 5Health News:QLT Announces Fourth Quarter and Year End 2008 Results 6Health News:QLT Announces Fourth Quarter and Year End 2008 Results 7Health News:QLT Announces Fourth Quarter and Year End 2008 Results 8Health News:QLT Announces Fourth Quarter and Year End 2008 Results 9Health News:QLT Announces Fourth Quarter and Year End 2008 Results 10Health News:QLT Announces Fourth Quarter and Year End 2008 Results 11Health News:QLT Announces Fourth Quarter and Year End 2008 Results 12Health News:QLT Announces Fourth Quarter and Year End 2008 Results 13Health News:QLT Announces Fourth Quarter and Year End 2008 Results 14Health News:QLT Announces Fourth Quarter and Year End 2008 Results 15Health News:QLT Announces Fourth Quarter and Year End 2008 Results 16Health News:QLT Announces Fourth Quarter and Year End 2008 Results 17Health News:QLT Announces Fourth Quarter and Year End 2008 Results 18Health News:QLT Announces Fourth Quarter and Year End 2008 Results 19Health News:United States Patent Office Rejects KCI's Patents 2Health News:United States Patent Office Rejects KCI's Patents 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: